Everest Medicines Limited (FRA:6HN)

Market Cap	1.53B
Revenue (ttm)	101.18M
Net Income (ttm)	-78.30M
Shares Out	n/a
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	24
Open	4.300
Previous Close	4.220
Day's Range	4.300 - 4.300
52-Week Range	4.000 - 8.250
Beta	n/a
RSI	36.93
Earnings Date	Mar 29, 2026

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 665
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6HN

Financial Performance

In 2024, Everest Medicines's revenue was 706.68 million, an increase of 461.16% compared to the previous year's 125.93 million. Losses were -1.04 billion, 23.3% more than in 2023.

Financial numbers in CNY